CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$63.99 USD
+2.89 (4.73%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $63.88 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
CRISPR Therapeutics AG's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CRSP 63.99 +2.89(4.73%)
Will CRSP be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
Other News for CRSP
Is CRSP showing upside potential? Crossed Above 50 Day Moving Average shows up after climbing 4.73%
CRISPR Therapeutics (CRSP) Gains as FDA Eases Approval Pathway
Gene editing therapy companies rise on word of streamlined FDA approval process
FDA to Expedite Gene-Editing Approval Process, Impacting CRSP
FDA to speed up gene editing therapy approvals, Bloomberg reports